Scientists at the University of Cambridge have announced the creation of a vaccine with a core component designed entirely through artificial intelligence, marking what they characterize as a world-first achievement in vaccine development. The researchers used genetic information from multiple coronaviruses gathered through surveillance programs to train an AI system to design a “super-antigen” capable of triggering immune protection across an entire family of viruses, including variants and potential animal-to-human transmission scenarios.
The approach represents a departure from conventional vaccine design methods, which typically focus on current viral strains. By analyzing diverse genetic codes from known coronaviruses, the AI generated a component intended to protect against mutations and emerging threats within the coronavirus family. Initial human trials involving 39 participants were conducted to assess safety, while a second trial with approximately 200 participants is planned to evaluate immune system effectiveness. Results published in the Journal of Infection indicated the immune response was “modest,” though researchers expressed optimism about the findings.
Experts outside the immediate research team acknowledged the potential significance of the work. A researcher involved in conducting trials at the University of Southampton noted that AI design showed particular promise for developing vaccines against viruses with high mutation rates. A director from the Oxford Vaccine Group emphasized that artificial intelligence could accelerate vaccine development more broadly by predicting immune responses and reducing development timelines.
The Cambridge team is expanding the approach to target other infectious disease threats. Research is underway on universal seasonal flu vaccines that would not require annual reformulation, an H5N1 bird flu vaccine, and vaccines against viral hemorrhagic fevers including Ebola. Government officials and health research leaders highlighted the potential of this technology to support global vaccine distribution and pandemic preparedness efforts.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI